Why does a functional label follow you from one doctor to the next?
Because a chart never forgets and rarely reconsiders. When benzodiazepine-induced neurological dysfunction, or BIND, is written up as functional neurological disorder, or FND, the label does not stay in one neurologist’s note. It travels, and every clinician who opens the record afterward reads it before they read you.
It shapes how a new tremor gets interpreted, which specialists will accept a referral, and whether an insurer will pay. Yet, the label was usually applied in good faith, by a doctor working inside a framework that has no line for BIND.
So, why does the mix-up happen, and what changes the record once it has? The second answer is paper.
What is BIND, and why does it look like nothing on a scan?
BIND is the name for the neurological, cognitive, and autonomic symptoms that can persist after long-term benzodiazepine use, including in people who tapered slowly and did everything right. The symptoms begin during use, during dose reductions, or after the last dose, and that timing is the heart of the diagnosis.
Professor C. Heather Ashton described the picture years ago without the acronym. Chapter III of the Ashton Manual, in its Table 3 of protracted withdrawal symptoms, lists tinnitus, tingling, numbness, burning limb pain, muscle pain, cramps, tremor, jerks, and shaking attacks, and says they gradually recede but may last at least a year and occasionally several. The 2020 United States Food and Drug Administration (FDA) label update says as much: physical dependence can occur when a benzodiazepine is taken steadily for several days to weeks, even as prescribed, and a protracted withdrawal syndrome can last from weeks to as long as twelve months.
Why is the scan normal? The first chapter of the Ashton Manual describes the receptors benzodiazepines act on becoming less responsive during long use. One theory is that they recover slowly afterward, a change in how the nervous system is tuned rather than in its structure, and no routine test measures tuning.
Functional neurological disorder is supposed to be a rule-in diagnosis.
FND is a real diagnosis, and a neurologist is supposed to make it on positive findings rather than on the absence of them. The rule-in signs are specific: Hoover’s sign for functional weakness, tremor that falls into step with a rhythm the examiner sets, and movements that stop when your attention is pulled elsewhere.
In practice it is not always arrived at that carefully. A normal magnetic resonance imaging (MRI) scan, a normal electroencephalogram (EEG), and no fit to a standard syndrome, and the note says functional because nothing else was on the menu. That default is where the BIND patient gets caught, and the Maudsley Deprescribing Guidelines make the point that withdrawal effects are often mistaken for a return of the original condition or for a new physical or mental health condition.
Three things about BIND make the mix-up easy.
First, the tests are normal. There is no MRI finding for BIND and the EEG shows no seizure activity. Professor Ashton recorded three patients whose numbness, spasms, and double vision were diagnosed as multiple sclerosis, a label that disappeared with the symptoms once they were off the drug. The same pattern appears in other specialties when jaw tension and neck dystonia in withdrawal are read as temporomandibular disorder.
Second, some BIND signs look functional on the surface. Tremor that waxes and wanes, symptoms that shift with attention, and bad days followed by ordinary ones are all real in BIND, and all sit on the list neurologists are taught to read as functional.
Third, the medication history is thin in the chart. If your years on a benzodiazepine and the taper that followed are not at the top of the history, the neurologist may never connect the picture to the drug. And, when the taper is recorded, it usually reads “completed uneventfully six months ago,” which few neurologists are trained to weigh as a live variable.
Start with a written medication timeline.
The most useful document you can bring is one page. It lists the benzodiazepine by name, the dose, how long you took it, how the taper went and when it ended, and beside that, when each symptom began and how it has behaved since. Ask that the page be scanned into the chart as a document, not summarized by whoever is typing.
Write it in the vocabulary of prescribed dependence. If the chart files your Klonopin (clonazepam) under past habits rather than under prescribed medications, every later reader starts from the wrong premise. Physical dependence is not addiction. A person who took a medication as prescribed and now has symptoms after stopping it has a medical condition caused by the medication, and a timeline that says so plainly does more work than any argument in a visit.
While you are writing it, resist any urge to prove a point by changing your taper. The 2020 label update is explicit that stopping a benzodiazepine abruptly, or reducing it too quickly, can bring on withdrawal reactions, including seizures, that can be life-threatening.
Ask that BIND be named, with its expansion.
Clinicians write what they are given. A short line you hand over, “presentation consistent with benzodiazepine-induced neurological dysfunction (BIND) following prescribed use and a completed taper,” gives the record a searchable term the next clinician can act on, and preserves the fact that the injury was iatrogenic, meaning caused by treatment.
Bring supporting material, kept short. The 2020 FDA label update is the strongest single page, because its boxed warning, which your neurologist can look up, says continued use can lead to clinically significant physical dependence. The Maudsley Deprescribing Guidelines are a reference text neurologists recognize, and the Benzodiazepine Information Coalition, or BIC, on whose medical advisory board Dr. Leeds serves, publishes clinical resources written for this conversation.
If FND is already in the chart, ask for a written amendment.
The Health Insurance Portability and Accountability Act, or HIPAA, gives you the right to ask that a record you believe is inaccurate be amended. The request goes in writing to the practice or hospital that created the note, and a refusal must come back to you in writing, ordinarily within sixty days. Keep it factual: the diagnosis does not reflect the medication history and the symptom chronology, and you are asking that BIND be added, alongside FND or as a correction.
They may say no. Unfortunately, a denial by itself does not make your request travel with the record. What does is a statement of disagreement, a short written note you file after the denial. Once it is on file, the provider must include your request, the denial, and your statement whenever that part of the record is disclosed, and without it they are included only if you ask for that separately.
So, if the answer is no, file the statement. It is the step most patients skip, and the one that does the work. If the answer is yes, ask which records were amended and whether the correction reached the other clinicians who received the original.
Ask that the negative findings be written down.
There is a difference between a note that says “functional etiology suspected” and one that says “Hoover’s sign negative, tremor did not entrain, FND rule-in signs tested and not present.” The first is an impression. The second is a set of findings, and findings are what the next neurologist reads.
So, when an examiner tests for those signs and does not find them, ask that the absence be recorded affirmatively, and ask in the room. That small request quietly removes the floor from under a functional label.
The record is changed with paper, not with persuasion.
Do not argue the diagnosis in the visit. The mechanism that produced it is institutional, fifteen-minute appointments and diagnostic defaults, and none of that is reversed by one patient disagreeing well.
Do not avoid mental health care out of fear that it confirms the functional label. BIND regularly brings anxiety, low mood, and trauma responses that deserve care in their own right, and treating them does not retroactively validate an FND diagnosis. Choose it with open eyes, since standard psychiatric treatment can make BIND worse, and if thoughts of harming yourself appear, call or text 988 or go to the nearest emergency department.
And do not let “it is probably BIND” become a label of its own. New weakness or numbness on one side of the body, a first seizure, a sudden loss of vision or hearing, a severe sudden headache, chest pain, or trouble speaking need emergency care the same day, whatever the chart says. BIND explains a great deal, and it does not explain everything.
The clinicians who wrote the label are usually not the problem.
Most neurologists who apply an FND label do it in good faith, within a diagnostic framework that has not yet made room for BIND, and the path forward is clinician education more than confrontation. Over time the label often softens and drops out of later notes as the paper keeps arriving.
Fortunately, this is a syndrome with a direction. The Ashton Manual says that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, and a record corrected one page at a time tends to lag behind the nervous system it describes. You will probably be better before the chart catches up, and the pages you filed will still be there for whoever reads it next.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.